Drug Utilisation Subcommittee outcome statement

PBAC

21 July 2021 - The outcome statement from the June 2021 Drug Utilisation Subcommittee meeting is now available.

The Drug Utilisation Subcommittee of the PBAC held its 102nd meeting on the 3 – 4 June 2021.

DUSC reviewed the utilisation of the following PBS medicines:

  • Evolocumab for heterozygous familial hypercholesterolaemia
  • Guanfacine hydrochloride for attention deficit hyperactivity disorder
  • Somatropin for growth hormone deficiency

Read DUSC outcome statement


Michael Wonder

Posted by:

Michael Wonder